Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Advances in the Understanding of Etiology (I)
-
1. Infection and autoimmunity: a two-way relationship
- Dr. Ricard Cervera
-
2. Autoimmunity and atherosclerosis
- Prof. Johan Frostegard
-
3. Endothelium and autoimmunity
- Prof. Pier Luigi Meroni
- Advances in the Understanding of Etiology (II)
-
4. Prolactin has a pathogenic role in systemic lupus erythematosus
- Prof. Luis Jara-Quezada
-
5. Sjögren's syndrome: current knowledge and future prospects
- Prof. Athanasios G. Tzioufas
-
6. Genetic and environmental triggers of autoimmune thyroid diseases
- Prof. Yaron Tomer
- Advances in Pathogenesis and Clinical Manifestation
-
8. Pathogenic mechanisms of autoantibodies: circulating and local antibodies that form immune complexes
- Dr. Luís Eduardo Coelho Andrade
-
9. Pathogenic mechanisms of autoantibodies: antibodies to intracellular and membrane-bound antigens
- Dr. Luís Eduardo Coelho Andrade
-
10. What causes primary biliary cholangitis?
- Dr. M. Eric Gershwin
-
11. Capillaroscopy in autoimmune rheumatic diseases
- Prof. Maurizio Cutolo
- Advances in Diagnostic Methodologies (I)
-
12. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
13. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
14. Diagnostic methods in autoimmunity
- Mr. Steven Binder
-
15. Systemic lupus erythematosus: novel aspects of pathogenesis and treatment 1
- Prof. Chaim Putterman
- Dr. Noa Schwartz
-
16. Systemic lupus erythematosus: novel aspects of pathogenesis and treatment 2
- Prof. Chaim Putterman
- Dr. Noa Schwartz
-
17. Novel aspects of systemic sclerosis
- Prof. Gabriele Valentini
- Advances in Diagnostic Methodologies (II)
-
18. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
-
19. Protective autoantibodies
- Prof. Elias Toubi
-
21. Rheumatic fever: a model of a post-infectious autoimmune disease
- Prof. Jorge Kalil
- Treatments of autoimmune diseases
-
22. Intravenous immunoglobulins: clinical evidence
- Prof. Shaye Kivity
- Latest Developments in the Field
-
23. Adjuvants and autoimmunity
- Dr. Eitan Israeli
-
24. Antiphospholipid syndrome (APS): from pathogenesis to treatment
- Prof. Roger Levy
-
25. Vitamin D and autoimmunity
- Dr. Shir Azrielant
-
26. Pregnancy in rheumatic diseases
- Prof. Pier Luigi Meroni
- Archived Lectures *These may not cover the latest advances in the field
-
27. Pathogenic mechanisms of autoantibodies
- Prof. Cees Kallenberg
-
28. B lymphocytes on the frontline of autoimmunity
- Prof. Pierre Youinou
-
29. Apoptotic cell clearance deficiency
- Prof. Martin Herrmann
-
30. Auto-antibodies as predictors of autoimmune disease
- Dr. Nicola Bizzaro
-
31. Innate immunity and natural autoantibodies
- Prof. Luc Mouthon
-
32. Accelerated atherosclerosis in autoimmune rheumatic disease
- Dr. Andrea Doria
-
33. Pregnancy in autoimmune rheumatic diseases
- Prof. Angela Tincani
-
36. Immunologic mechanisms in systemic lupus erythematosus
- Prof. Kok-Yong Fong
-
37. Osteoimmunology
- Prof. João Eurico Fonseca
- Ms. Joana Caetano-Lopes
-
38. ANCA-associated systemic vasculitides
- Prof. Loic Guillevin
-
39. The common origin for diverse autoimmune diseases
- Prof. Juan-Manuel Anaya
-
40. Anti-cytokine therapy in rheumatoid arthritis
- Prof. Piercarlo Sarzi-Puttini
-
41. Sjogren's syndrome: autoimmune epithelitis
- Prof. Haralampos Moutsopoulos
-
42. Vitamin D and autoimmunity
- Dr. Howard Amital
-
43. Intravenous immunoglobulins: myth and reality
- Prof. Zera Tellier
Printable Handouts
Navigable Slide Index
- Introduction
- Sjögren's syndrome - Autoimmune Epithelitis
- Sjögren’s syndrome
- Autoimmune rheumatic diseases
- Immunopathology
- Autoantibodies to cellular autoantigens
- Autoantibodies & clinical associations (1)
- Autoantibodies & clinical associations (2)
- High heterogeneity (1)
- Clinical manifestations (1)
- Clinical manifestations (2)
- Wide clinical spectrum - autoimmune epithelitis
- Autoimmune lesion
- Autoimmune lesion: cytokines
- Antigen-driven autoimmune response
- The salivary glands and autoantibody production
- Central role of epithelial cells - main findings
- Clinical manifestations (3)
- Peri-epithelial vs extra-epithelial
- High heterogeneity (2)
- Autoimmune MSG lesions (1)
- Autoimmune MSG lesions (2)
- Germinal centers
- B cell disturbances
- Heterogeneous B-cell population
- High heterogeneity (3)
- Outcome
- Wide clinical spectrum
- Mortality in SS with or without lymphoma
- Malignant lymphoma
- Clinical characteristics of lymphoma
- MALT lymphoma - extranodal involvement
- Clinical risk factors
- Serological / hematological markers
- Histological markers: minor salivary glands (1)
- Histological markers: minor salivary glands (2)
- Predictors of lymphoma development in SS
- Adverse prognostic factors
- High heterogeneity (4)
- Biologic treatments
- Targeted treatments (1)
- Targeted treatments (2)
- Studies: failure to conclude
- Definition
- Mission
- Biomarkers (1)
- microRNAs (miRNAs)
- miR200b miRNAs
- miR200b-5p expression in MSGs (1)
- miR200b-5p expression in MSGs (2)
- Biomarkers (2)
- We might be more efficient if…
- HarmonicSS
- The consortium
- Harmonization process
- A conceptual step-wise categorization
- From biomarkers to precision medicine
- Acknowledgements
Topics Covered
- Introduction to Sjögren's syndrome
- Humoral and cellular autoimmune responses in Sjögren's syndrome
- Description of heterogenic clinical features of disease
- Pathogenetic/immunopathologic aspects and associations with clinical phenotypes
- The need for precise therapeutic approaches
- Development and features of lymphoma in Sjögren's syndrome
- Risk factors for development of severe disease
- Biomarkers for disease severity, outcome and lymphoma
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Tzioufas, A.G. (2018, November 29). Sjögren's syndrome: current knowledge and future prospects [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/UTHJ4820.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Athanasios G. Tzioufas has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Sjögren's syndrome: current knowledge and future prospects
Published on November 29, 2018
44 min
A selection of talks on Immunology
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Athanasios Tzioufas.
I'm Professor of Medicine and Rheumatology in
the department of Pathophysiology in the School of Medicine in Athens.
My mission today is to present
our current knowledge and future prospects on Sjogren's syndrome.
0:16
Sjogren's syndrome or also called autoimmune epithelitis is
a common disease since it affects 0.5 to one percent of adult females.
As you see, there are nine females
versus one male that they are affected from the disease.
As you will see in the next slides,
it has a wide clinical spectrum including
organ-specific disease affecting only the excrete glands.
It can be in the form of systemic disease,
and finally some patients,
around five percent, may end by developing non-Hodgkin's B-cell lymphoma.
Sjogren's syndrome has an easy lesion to be studied that is the minor salivary glands.
It can be taken without significant morbidity from patients.
By studying this lesion,
it can also share as a paradigm for other autoimmune disorders.
1:17
Sjogren's syndrome is a disease that affects ladies,
as I told you previously,
particularly in the middle ages.
You see in the slide that with the red dot line,
the disease is appear usually in the middle ages,
I told you, the peak around the middle age of 50's,
but the onset of the disease come several years earlier.
There are also some clinical forms of the disease,
as you see here,
that is normal individuals that they may
have autoantibodies of Sjogren's syndrome before the disease develop.
So, between the onset of symptoms at diagnosis,
they are usually seven years elapsed.